Inflammation and acute stroke

Current Opinion in Neurology

Volumn 11, Issue 1, 1998, Pages 45-49

  Becker, Kyra J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE;

BRAIN ISCHEMIA; FEVER; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; REVIEW; STROKE;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR DISORDERS; HUMANS; INFLAMMATION; LEUKOCYTES;

EID: 0031982968     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199802000-00008     Document Type: Review

References (66)

1. Barkalow FJ, Goodman MJ, Gerritsen ME, Mayadas TN. Brain endothelium lacks one of two pathways of P-selectin-mediated neutrophil adhesion. Blood 1996; 88:4585-4593.
2. dos Santos W, Rahman J, Klein N, Male D. Control of lymphocyte adhesion to brain and aortic endothelium: ICAM-1, VCAM-1 and negative charge. J Neuroimmunol 1996; 66:125-134.
3. Navratil E, Couvelard A, Rey A, Henin D, Scoazec JY. Expression of cell adhesion molecules by microvascular endothelial cells in the cortical and subcortical regions of the normal human brain: an immunohistochemical analysis. Neuropathol Appl Neurobiol 1997; 23:68-80.
4. Bo L, Peterson JW, Mork S, Hoffman PA, Gallatin WM, Ransohoff RM, et al. Distribution of immunoglobulin supertamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55:1060-1072.
5. Suzuki H, Abe K, Tojo S, Morooka S, Kimura K, Mizugaki M, et al. Postischemic expression of P-selectin immunoreactivity in rat brain. Neurosci Lett 1997; 228:151-154.
6. Zhang RL, Chopp M, Zhang ZG, Phillips ML, Hosenbloom CL, Cruz R, et al. E-selectin in focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 1996; 16:1126-1136.
7. Stanimirovic D, Shapiro A, Wong J, Hutchison J, Durkin J. The induction of ICAM-1 in human cerebromicrovascular endothelial cells (HCEC) by ischemia-like conditions promotes enhanced neutrophil/HCEC adhesion. J Neuroimmunol 1997; 76:193-205.
8. Haring HP, Berg EL, Tsurushita N, Tagaya M, del Zoppo GJ. E-selectin appears in nonischemic tissue during experimental focal cerebral ischemia. Stroke 1996; 27:1386-1391. Using a non-human primate model of transient focal ischemia, the authors show that E-selectin immunoreactivity is present within the ischemic basal ganglia by 2 hours after reperfusion (following 3 hours of middle cerebral artery occlusion). The amount of E-selectin in the ischemic basal ganglia increased at 24 hours at which time it could also be identified within the non-ischemic basal ganglia.
9. Yoshimoto T, Houkin K, Tada M, Abe H. Induction of cytokines, chemokines and adhesion molecule mRNA in a rat forebrain reperfusion model. Acta Neuropathol (Berl) 1997; 93:154-158.
10. Lindsberg PJ, Carpen O, Paetau A, Karjalainen-Lindsberg M-L, Kaste M. Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Stroke 1996; 94:939-945.
11. Shyu KG, Chang H, Lin CC. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke. J Neurol 1997; 244:90-93.
12. Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996; 20:445-452.
13. Hartl R, Schurer L, Schmid-Schönbein GW, del Zoppo GJ: Experimental antileukocyte interventions in cerebral ischemia. J Cereb Blood Flow Metab 1996; 16:1108-1119.
14. Hallenbeck JM. Inflammatory reactions at the blood-endothelial interface in acute stroke. Adv Neurol 1996; 71:281-297. This is a very thorough review of the many mechanisms by which leukocytes and other mediators of the inflammatory process can contribute to ischemic brain injury in stroke.
15. Kato H, Kogure K, Liu XH, Araki T, Itoyama Y. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain Res 1996; 734:203-212.
16. Zhang Z, Chopp M, Powers C. Temporal profile of microglial response following transient (2 h) middle cerebral artery occlusion. Brain Res 1997; 744:189-198.
17. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996; 27:1739-1743.
18. Witte OW, Stoll G. Delayed and remote effects of focal cortical infarctions: secondary damage and reactive plascticity. Adv Neurol 1997; 73:207-227.
19. Chopp M, Li Y, Jiang N, Zhang RL, Prostak J. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. J Cereb Blood Flow Metab 1996; 16:578-584.
20. Zhang RL, Chopp M, Jiang N, Tang WX, Prostak J, Manning AM, et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 1995; 27:1438-1442.
21. Soriano SG, Lipton SA, Wang YF, Xiao M, Springer TA, Gutierrez-Ramos JC, et al. Intercellular adhesion molecule-1-deficient mice are less susceptible to cerebral ischemia-reperfusion injury. Ann Neurol 1996; 39:618-624.
22. Connolly E. Jr, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD, et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97:209-216.
23. Connolly ES Jr, Winfree CJ, Prestigiacomo CJ, Kim SC, Choudhri TF, Hoh BL, et al. Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circ Res 1997; 81:304-310.
24. Morikawa E, Zhang SM, Seko Y, Toyoda T, Kirino T. Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin. Stroke 1996; 27:951-955; discussion 956.
25. Dawson DA, Ruetzler CA, Carlos TM, Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and microcirculatory perfusion in acute stroke in the SHR. Keio J Med 1996; 45:248-252: discussion 252-23.
26. The Enlimomab Acute Stroke Trial Investigators. The enlimomab acute stroke trial: final results. Neurology 1997; 48:A270.
27. Li K, Futrell N, Tovar JS, Wang LC, Wang DZ, Schultz LR. Gender influences the magnitude of the inflammatory response within embolic infarcts in young rats. Stroke 1996; 27:498-503.
28. Saito K, Suyama K, Nishida K, Sei Y, Basile A. Early increases in TNF-γ, IL-6, and IL-1β levels following transient cerebral ischemia in gerbil brain. Neurosci Lett 1996; 206:149-152.
29. Uno H, Matsuyama T, Akita H, Nishimura H, Sugita M. Induction of tumor necrosis factor-α in the mouse hippocampus following transient forebrain ischemia. J Cereb Blood Flow Metab 1997; 17:491-499.
30. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, et al. Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997; 94:2007-2012.
31. Becker KJ, McCarron RM, Ruetzler C, Laban O, Sternberg E, Flanders KC, et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A 1997. The authors use a novel approach to limit the inflammatory reaction within the brain following stroke. Capitalizing on the release of central nervous system antigens into the circulation following ischemic breakdown of the blood-brain barrier, they were able to induce a relatively antigen and organ specific alteration in the immune response which resulted in a decrease in infarct size.
32. Wang X, Barone F, Aiyar N, Feuerstein GZ. Interleukin-1 receptor and receptor antagonist gene expression after focal stroke in rats. Stroke 1997; 28:155-162.
33. Krupinski J, Kumar P, Kumar S, Kaluza J. Increased expression of TGF-β1 in brain tissue after ischemic stroke in humans. Stroke 1996; 27:852-857.
34. Hara H, Fink K, Endres M, Friedlander RM, Gagliardini V, Yuan J, et al. Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J Cereb Blood Flow Metab 1997; 17:370-375. Using a transgenic mouse with a dominant negative mutation of the interleukin-1β converting enzyme, the authors show that stroke size and cerebral edema were decreased following 3 hours of ischemia and 24 hours of reperfusion. This was associated with a 77% decrease in IL-β production at 30 minutes after reperfusion and a decrease in DNA fragmentation at 24 hours in the mutant mice.
35. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996; 16:932-940.
36. Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996; 138:206-213.
37. Stroemer RP, Rothwell NJ. Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. J Cereb Blood Flow Metab 1997; 17:597-604.
38. Loddick SA, Wong ML, Bongiorno PB, Gold PW, Licinio J, Rothwell NJ. Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem Biophys Res Commun 1997; 234:211-215.
39. Barone FC, Arvin B, White R, Miller A, Webb C, Willette R, et al. Tumor necrosis factor-α: a mediator of focal ischemic brain injury. Stroke 1997; 28:1233-1244. Whether or not TNF-α contributes to ischemic brain injury and how it does so has been debated. In this paper the authors examine the role of TNF-α in cerebral ischemia in vivo. Using several different strategies they show that TNF-α is clearly detrimental to the ischemic brain. Furthermore, they provide data from cell culture that show that TNF-α does not appear to directly affect neuronal function of survivial, which suggests a role for glial cells or inflammatory cells in the brain injury that occurs in vivo.
40. Nawashiro H, Martin D, Hallenbach JM. Inhibition of tumour necrosis factor and ameliroation of brain infarction in mice. J Cereb Blood Flow Metab 1997; 17:229-232.
41. Dawson D, Martin D, Hallenbach JM. Inhibition of TNF-α reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett 1996; 218:41-44.
42. ••], but the experimental models differ greatly and transgenic animals always introduce the possibility that the fundamental biology of the organism has been changed.
43. Probert L, Selmaj K. TNF and related molecules: trends in neuroscience and clinical applications. J Neuroimmunol 1997; 72:113-117.
44. Darnay BG, Aggarwal BB. Early events in TNF signaling: a story of associations and dissociations. J Leukoc Biol 1997; 61:559-566. The authors provide a very thorough and detailed review of how TNF signals through its receptors. TNF receptor activation can result in either apoptosis or activation of the nuclear factor-kappa B (NF-κB), the latter resulting in upregulation of mediators of the inflammatory cascade.
45. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindegarde F, Ohlsson K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic vascular disease. Stroke 1996; 27:1734-1738.
46. van Kooten F, Ciabattoni G, Patrono C, Dippel D, WJ Koudstaal PJ. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke 1997; 28:1557-1563.
47. Iijima T, Sawa H, Shiokawa Y, Saito I, Ishii H, Nakamura Z, et al. Thromboxane synthetase inhibitor ameliorates delayed neuronal death in the CA1 subfield of the hippocampus after transient global ischemia in gerbils. J Neurosurg Anesthesiol 1996; 8:237-242.
48. Bazan NG, Allan G. Platelet-activating factor is both a modulator of synaptic function and a mediator of cerebral injury and inflammation. Adv Neurol 1996; 71:475-482.
49. Liu XH, Eun BL, Silverstein FS, Barks JD. The platelet-activating factor antagonist BN 52021 attenuates hypoxic-ischemic brain injury in the immature rat. Pediatr Res 1996; 40:797-803.
50. Feuerstein GZ. Platelet-activating factor: a case for its role in CNS function and brain injury. J Lipid Mediat Cell Signal 1996; 14:109-114.
51. Reith J, Jorgensen H, Pedersen P, Nakayama H, Raaschou H, Jeppesen L, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, and mortality. Lancet 1996; 347:422-425. In a prospective and consecutive study, the authors evaluated 390 stroke patients admitted to the hospital within 6 hours of stroke onset. They found that patients with mild hypothermia upon admission had a decrease in morbidity (as measured by the Scandinavian Stroke Scale) and mortality while those patients with hyperthermia had an increase in morbidity and mortality. For each degree (centigrade) rise in temperature the relative risk of poor outcome rose by 2.2. While this study clearly shows an association between fever and outcome following stroke, it does not address causality.
52. Dietrich WD, Busto R, Globus MY, Ginsberg MD. Brain damage and temperature: cellular and molecular mechanisms. Adv Neurol 1996; 71:177-194. The authors provide a thorough review on the potential mechanisms by which hyperthermia contributes to ischemic brain injury.
53. Wood SC, Gonzales R. Hypothermia in hypoxic animals: mechanisms, mediators, and functional significance. Comp Biochem Physiol B Biochem Mol Biol 1996; 113:37-43.
54. Luheshi GN, Stefferl A, Turnbull AV, Dascombe MJ, Brouwer S, Hopkins SJ, et al. Febrile response to tissue inflammation involves both peripheral and brain IL-1 and TNF-α in the rat. Am J Physiol 1997; 272:R862-R868.
55. Luheshi G, Miller AJ, Brouwer S, Dascombe MJ, Rothwell NJ, Hopkins SJ. Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat. Am J Physiol 1996; 270:E91-E95.
56. Missler U, Wiesman M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997; 28:1956-1960.
57. Buttner T, Weyers S, Posten T, Sprengelmeyer R, Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 1997, 28:1961-1965.
58. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6. transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke 1996; 27:1553-1557.
59. Henrich-Noack P, Prehn JHM, Krieglstein J. TGF-β1 protects hippocompal neuronas against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms. Stroke 1996; 27:1609-1614.
60. Mattson M, Barger S, Furukawa K, AJ R, Wyss-Coray T, Mark R, et al. Cellular signaling roles of TGF β, TNF α and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev 1997; 23:47-61.
61. Ren R, Flanders K. Transforming growth factors-β protect primary rat hippocampal neuronal cultures from degeneration induced by beta-amyloid peptide. Brain Res 1996; 732:16-24.
62. Bova IY, Bornstein NM, Korczyn AD. Acute infection as a risk factor for stroke. Stroke 1996; 27:2204-2206.
63. Macko R, Ameriso S, Barndt R, Clough W, Weiner J, Fisher M. Precipitants of brain infarction. Roles of preceding infection/inflammation and recent psychological stress. Stroke 1996; 27:1999-2004.
64. Macko R, Ameriso S, Gruber A, Griffin J, Fernandez J, Barndt R, et al. Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke 1996; 27:2005-2011.
65. Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res 1996; 82:245-255.
66. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979. This report is an intriguing look back at the Physician's Health Study that found the risk of ischemic stroke and myocardial infarction in a cohort of apparently healthy young men was related to the plasma level of C-reactive protein. Furthermore, aspirin was only beneficial in preventing myocardial infarction in those men with the highest levels of C-reactive protein, suggesting that aspirin was acting as an anti-inflammatory agent as opposed to an anti-platelet agent.